Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 301–400 of 1,004
Hüsser, A. P., & Ohnmacht, T. (2023) · Tourism Management · doi:10.1016/j.tourman.2023.104734 · Cited by 33
“The BNT162b2 (Pfizer Biontech) mRNA vaccine, for example, is efficient against the disease and severe illness, even against new variants, especially when three doses have been administered (e.g., Andrews et al., 2022; Barda et al., 2021; Leshem & Lopman, 2021; Thomas et al., 2021).”
Kun, Á., Hubai, A. G., Král, A., Mokos, J., Mikulecz, B. Á., & Radványi, Á. (2023) · Biologia Futura · doi:10.1007/s42977-023-00159-2 · Cited by 31
Prather, A. A., Dutcher, E. G., Robinson, J. E., Lin, J., Blackburn, E. H., Hecht, F. M., Mason, A. E., Fromer, E., Merino, B., Frazier, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33320-x · Cited by 32
Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill, B., Romero, A. R., & Fenton, O. S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00721 · Cited by 33
Causal interpretation of the hazard ratio in randomized clinical trials
Fay, M. P., & Li, F. (2024) · Clinical Trials · doi:10.1177/17407745241243308 · Cited by 46
“These cumulative incidences and hazard ratios are similar to those in Figure 2 of Thomas et al. 44 An important consideration is the distribution of frail individuals.”
InfluentialThe real-time infection hospitalisation and fatality risk across the COVID-19 pandemic in England
Ward, T., Fyles, M., Glaser, A., Paton, R. S., Ferguson, W., & Overton, C. E. (2024) · Nature Communications · doi:10.1038/s41467-024-47199-3 · Cited by 32
Assawasaksakul, T., Lertussavavivat, T., Sathitratanacheewin, S., Oudomying, N., Vichaiwattana, P., Wanlapakorn, N., Poovorawan, Y., Avihingsanon, Y., Assawasaksakul, N., Buranapraditkun, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10060853 · Cited by 35
Sandoval, C., Guerrero, D., Muñoz, J., Godoy, K., Souza‐Mello, V., & Farías, J. G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2156861 · Cited by 31
“Finally, the efficacy of the BNT162b2 vaccine against severe disease with an onset after receiving the first dose was approximately 97% [47].”
BackgroundZhao, Y., Du, J., Li, Z., Xu, Z., Wu, Y., Duan, W., Wang, W., Zhang, T., Xu, J., Wu, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28509 · Cited by 33
“A large number of studies have shown that the efficacy of the COVID‐19 vaccine was as high as 89%–95%, with an excellent safety record.(7,8) The severity of COVID‐19 was significantly different between vaccinated and unvaccinated individuals.”
BackgroundAn update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies
Spicuzza, L., Campagna, D., Maria, C. D., Sciacca, E., Mancuso, S., Vancheri, C., & Sambataro, G. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023020 · Cited by 30
“have been produced and already implemented in most countries [137].”
BackgroundDYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine, M. S., Cai, W. L., Wei, J., Alfajaro, M. M., Filler, R. B., Biering, S. B., Sarnik, S. A., Chow, R. D.-W., Patil, A., Cervantes, K. S., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002097 · Cited by 30
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Joshi, G., Borah, P., Thakur, S., Sharma, P., Mayank, M., & Ramarao, P. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1995283 · Cited by 30
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years
Funk, P. R., Yogurtcu, O. N., Forshee, R. A., Anderson, S. A., Marks, P. W., & Yang, H. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.030 · Cited by 29
“We assumed the vaccine has at least 6 months of protection since this is the period examined by Pfizer in their ongoing study at the time of this analysis [4].”
Trends in Clinical Presentation, Management, and Outcomes of STEMI in Patients With COVID-19
García, S., Dehghani, P., Stanberry, L. I., Grines, C. L., Patel, R. A. G., Nayak, K. R., Singh, A., Htun, W. W., Kabour, A., Ghasemzadeh, N., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.345 · Cited by 29
“NACMI was designed in early 2020 before the commercialization of vaccines against COVID-19.”
InfluentialBoulouis, C., Kammann, T., Cuapio, A., Parrot, T., Gao, Y., Mouchtaridi, E., Wullimann, D., Lange, J., Chen, P., Akber, M., et al. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00484-7 · Cited by 29
Dave, D., Fu, W., & Yang, M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4509 · Cited by 29
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Guan, X., Yang, Y., & Du, L. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2211153 · Cited by 30
“The majority of the currently approved or trialed COVID-19 vaccines target the SARS-CoV-2 S protein [119,123–126].”
BackgroundTracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
de Assis, F. L., Hoehn, K. B., Zhang, X., Kardava, L., Smith, C. D., Merhebi, O. E., Buckner, C. M., Trihemasava, K., Wang, W., Seamon, C. A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112780 · Cited by 31
“2,3 Despite the strong protective effects of mRNA and other SARS-CoV-2 vaccines, numerous studies have shown that there is a wide range of immune responses to the vaccines, driven in part by host factors such as age, immune deficiencies, and other underlying conditions.”
Yuan, J., Lam, W., Xiao, J., Ni, M. Y., Cowling, B. J., & Liao, Q. (2022) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbac184 · Cited by 29
Salvagno, G. L., Henry, B. M., Pighi, L., NITTO, S. D., Gianfilippi, G., & Lippi, G. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1184 · Cited by 28
Haranaka, M., Baber, J., Ogama, Y., Yamaji, M., Aizawa, M., Kogawara, O., Scully, I. L., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27316-2 · Cited by 28
Self-citationSARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets
Shivshankar, P., Karmouty‐Quintana, H., Mills, T., Doursout, M., Wang, Y., Czopik, A. K., Evans, S. E., Eltzschig, H. K., & Yuan, X. (2022) · Inflammation · doi:10.1007/s10753-022-01656-7 · Cited by 30
“As of February 2022, FDA has approved SARS-CoV-2 RNA vaccine from Pfizer-BioNTech and Moderna that have shown 90–95% protective efficacy in phase III clinical trials [183, 184].”
Yang, S. L., Ripen, A. M., Leong, C. T., Lee, J. V., Yen, C. H., Chand, A. K., Koh, K., Rahim, N. A. B. A., Gokilavanan, V., Mohamed, N. N. E., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2065936 · Cited by 29
Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Mazuecos, A., Villanego, F., Zárraga, S., López, V., Oppenheimer, F., Llinàs-Mallol, L., Hernández, A. M. G., Rivas, A., Ruiz-Fuentes, M. C., Toapanta, N., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004119 · Cited by 28
“First, it is known that there is a reduction in the mRNA vaccine efficacy in the following 4 to 6 mo after the second dose in the general population.(4,32) This could have more serious consequences in KTs because the vaccine produces a lower immune response in them.”
BackgroundRecent advances in versatile inverse lyotropic liquid crystals
Shan, X., Luo, L., Yu, Z., & You, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.036 · Cited by 29
Zamfir, M.-A., Moraru, L., Dobrea, C. M., Scheau, A.-E., Iacob, S. A., Moldovan, C., Scheau, C., Căruntu, C., & Căruntu, A. (2022) · Medicina · doi:10.3390/medicina58070874 · Cited by 28
Hunagund, S., Golan, Y., Asiodu, I. V., Prahl, M. K., & Gaw, S. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910383 · Cited by 30
“These vaccines have been found to be highly efficient in prevention of severe COVID-19 disease (83, 84) and to be safe for administration during pregnancy and lactation (85–95).”
BackgroundAlfonso, R., Lin, J., Kirschner, V., Lei, J., Feuer, G., Malin, M. L., Liu, J., Roche, M., & Sadiq, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926318 · Cited by 30
Nejad, M.-M. M., Shobeiri, P., Dehghanbanadaki, H., Tabary, M., Aryannejad, A., Ghadery, A. H., Shabani, M., Moosaie, F., SeyedAlinaghi, S., & Rezaei, N. (2022) · Virology Journal · doi:10.1186/s12985-022-01858-3 · Cited by 28
Scheu, M., & Kuckertz, A. (2022) · International Entrepreneurship and Management Journal · doi:10.1007/s11365-022-00815-4 · Cited by 29
Tjilos, M., Tamlyn, A. L., Ragan, E. J., Assoumou, S. A., Barnett, K. G., Martin, P., Perkins, R. B., Linas, B. P., & Drainoni, M. (2023) · BMC Public Health · doi:10.1186/s12889-023-15198-6 · Cited by 29
Wu, J.-D., Li, J., Liu, J., Wang, H., Zhou, G. H., Li, J., Wu, D., Chen, X., Feng, Y.-X., Qi, X., et al. (2023) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(23)00199-8 · Cited by 24
A potential association between COVID-19 vaccination and development of Alzheimer’s disease
Roh, J. H., Jung, I., Suh, Y., & Kim, M. H. (2024) · QJM · doi:10.1093/qjmed/hcae103 · Cited by 28
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 31
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Gumeni, S., Malandrakis, P., Papanagnou, E., Kastritis, E., Trougakos, I. P., & Dimopoulos, M. A. (2021) · Life · doi:10.3390/life11101077 · Cited by 29
“2) at 6 months following vaccination [12].”
Mathur, S., Chaturvedi, A., & Ranjan, R. (2025) · Nanoscale Advances · doi:10.1039/d5na00044k · Cited by 30
“56 Lipids used as delivery vehicles are categorized as cationic or ionizable lipids.”
Batatinha, H., Baker, F. L., Smith, K. A., Zúñiga, T. M., Pedlar, C. R., Burgess, S. C., Katsanis, E., & Simpson, R. J. (2021) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00629.2021 · Cited by 27
Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women
Shen, C., Fu, Y.-C., Lin, Y.-P., Shen, C., Sun, D.-J., Shen, C., & Cheng, C. (2022) · Vaccines · doi:10.3390/vaccines10010101 · Cited by 28
Choi, J. H., Kim, Y. R., Heo, S. T., Oh, H., Kim, M.-S., Lee, H. R., & Yoo, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827306 · Cited by 29
“In addition, the neutralization against the omicron variant was lower than that against the delta variant in participants who had received two and three doses of the BNT162b2 mRNA vaccine (5), and the durability of the effect of the third dose of vaccine against Covid-19 is yet to be determined.”
BackgroundApplication of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
“Clinical studies with two LNP-based mRNA vaccines against the SARS-CoV2 virus during the pandemic have confirmed the favorable results, showing a strong efficacy across different populations, leading to regulatory approval despite the short-term follow-up period [54,55].”
ResultMultiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review
Nabizadeh, F., Ramezannezhad, E., Kazemzadeh, K., Khalili, E., Ghaffary, E. M., & Mirmosayyeb, O. (2022) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2022.08.012 · Cited by 29
Goldman, R., Murthy, N. T. V., Trent, N., Balakrishnan, A., Chivukula, S. V., Danz, H., Tibbitts, T. J., Dias, A., Vargas, J., Cooper, D. L., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122243 · Cited by 28
Self-citationDevelopment of COVID-19 vaccine policy — United States, 2020–2023
Oliver, S. E., Wallace, M. M., Twentyman, E., Moulia, D., Godfrey, M., Link‐Gelles, R., Meyer, S. A., Fleming-Dutra, K. E., Hall, E., Wolicki, J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.022 · Cited by 27
“A clinical trial was also conducted to evaluate the immunogenicity, efficacy, and safety of the Pfizer-BioNTech COVID-19 Vaccine among children 6 months through 4 years of age[37].”
Why promoting a COVID-19 vaccine booster dose?
Loubet, P., Laureillard, D., Martin, A., Larcher, R., & Sotto, A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100967 · Cited by 27
Kim, B., Lee, H. J., Jeong, C. Y., Yeom, S. W., Park, D. W., Park, T. S., Moon, J., Kim, T., Sohn, J. W., Yoon, H. J., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1295457 · Cited by 28
Jutel, M., Torres, M. J., Palomares, Ó., Akdiş, C. A., Eiwegger, T., Untersmayr, E., Barber, D., Zemelka‐Wiącek, M., Kosowska, A., Palmer, E., et al. (2022) · Allergy · doi:10.1111/all.15252 · Cited by 26
Sikora, D., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10030437 · Cited by 26
Gao, P., Cai, S., Liu, Q., Du, M., Liu, J., & Liu, M. (2022) · Vaccines · doi:10.3390/vaccines10030421 · Cited by 26
“7%, respectively, with significance compared with the control group [7,8,10,22].”
BackgroundWang, R., Sun, C., Ma, J., Yu, C., Kong, D., Chen, M., Liu, X., Zhao, D., Gao, S., Kou, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10050702 · Cited by 26
Abouzid, M., Ahmed, A. A., El‐Sherif, D. M., Alonazi, W. B., Eatmann, A. I., Alshehri, M. M., Saleh, R., Ahmed, M. H., Aziz, I. A., Abdelslam, A. E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081270 · Cited by 27
“During the follow-up process of 6 months, participants in the BNT162b2 vaccine clinical study revealed that effectiveness towards infection declined by around 6% every 8 weeks [16].”
COVID-19 Vaccines' Protection Over Time and the Need for Booster Doses; a Systematic Review.
Dadras, O., SeyedAlinaghi, S., Karimi, A., Shojaei, A., Amiri, A., Mahdiabadi, S., Fakhfouri, A., Razi, A., Mojdeganlou, H., Mojdeganlou, P., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1582 · Cited by 26
“vaccine after six months, silencing the concerns and showing its sufficient protection during this time (9).”
BackgroundGao, P., Kang, L., Liu, J., & Liu, M. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00680-9 · Cited by 26
Nano-based theranostic approaches for infection control: current status and perspectives
Huang, R., Hu, Q., Ko, C.-N., Tang, F. K., Xuan, S., Wong, H. M., Jin, L., Li, X., & Leung, K. C. (2023) · Materials Chemistry Frontiers · doi:10.1039/d3qm01048a · Cited by 31
SARS-CoV-2 and COVID-19: A Narrative Review
Blann, A. D., & Heitmar, R. (2022) · British Journal of Biomedical Science · doi:10.3389/bjbs.2022.10426 · Cited by 27
Chin, E. T., Leidner, D., Zhang, Y., Long, E., Prince, L., Schrag, S. J., Verani, J. R., Wiegand, R. E., Alarid‐Escudero, F., Goldhaber‐Fiebert, J. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1032 · Cited by 27
“We found lower levels of estimated effectiveness for the fully vaccinated group over this extended period—an expected result, and a trend seen in the 6-month vaccine efficacy clinical trial for the BNT162b2 vaccine [22].”
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Evangelakou, Z., Gavriatopoulou, M., Manola, M. S., Malandrakis, P., Gianniou, D. D., Kastritis, E., Trougakos, I. P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020338 · Cited by 29
Dulovic, A., Strengert, M., Ramos, G. M., Becker, M., Griesbaum, J., Junker, D., Lürken, K., Beigel, A., Wrenger, E., Lonnemann, G., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2804.211907 · Cited by 25
“Although studies have indicated that differences exist in protection and antibody responses (21) after different COVID-19 vaccination schedules, our study of Pfizer’s BNT162b2 represents a real-world situation for most dialysis patients.”
BackgroundInfluentialChen, X., Wang, W., Chen, X., Wu, Q., Sun, R., Ge, S., Zheng, N., Lu, W., Yang, J., Rodewald, L. E., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02249-9 · Cited by 27
“the second dose, for an average decline of 6% every 2 months [29].”
BackgroundKlaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac438 · Cited by 26
“Antibody titers in vaccinated individuals are believed to wane at similar rates [13], although vaccine efficacy against symptomatic SARS-CoV-2 infection has been shown to remain robust in the first 6 months after inoculation [20, 21].”
Onyeaghala, A., Anyiam, A., Husaini, D. C., Onyeaghala, E., & Obi, E. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01627 · Cited by 17
Clairon, Q., Prague, M., Planas, D., Bruel, T., Hocqueloux, L., Prazuck, T., Schwartz, O., Thiébaut, R., & Guedj, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011282 · Cited by 29
Reynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 26
Engineered Nanomaterials for Immunomodulation: A Review
Singh, R., Kumawat, M., Gogoi, H., Madhyastha, H., Lichtfouse, É., & Daima, H. K. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00940 · Cited by 25
Yuan, J., Xu, Y., Wong, I. O. L., Lam, W., Ni, M. Y., Cowling, B. J., & Liao, Q. (2024) · Nature Communications · doi:10.1038/s41467-023-44650-9 · Cited by 26
COVID-19 vaccine decisions: considering the choices and opportunities
Hotez, P. J., Nuzhath, T., Callaghan, T., & Colwell, B. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104811 · Cited by 27
Zhang, R., Khong, K.-W., Leung, K., Liu, D., Fan, Y., Lu, L., Chan, P.-C., Chen, L., To, K. K., Chen, H., et al. (2021) · Vaccines · doi:10.3390/vaccines9121442 · Cited by 25
“For the third booster dose in vaccinees, two clinical studies report a reduced effectiveness of the BNT162b2 vaccine against SARS-CoV-2 at 6 months after their first dose [32,33].”
BackgroundDarraj, M., & Al-Mekhlafi, H. (2022) · Vaccines · doi:10.3390/vaccines10020223 · Cited by 17
Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
Suleyman, G., Fadel, R. A., Brar, I., Kassab, R., Khansa, R., Sturla, N., Alsaadi, A., Latack, K. A., Miller, J. B., Tibbetts, R. J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac116 · Cited by 26
“9%) 4 months after the second dose [10].”
Gesser‐Edelsburg, A., Hijazi, R., & Cohen, R. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.887579 · Cited by 25
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
Havervall, S., Marking, U. W., Greilert‐Norin, N., Gordon, M., Ng, H., Christ, W., Phillipson, M., Nilsson, P., Hober, S., Blom, K. G., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1388 · Cited by 27
“46 47 48 Clinical trials and post marketing effectiveness data have shown that currently used COVID49 19 vaccines protect strongly against hospitalization and death (1-3).”
Siller, A., Seekircher, L., Wachter, G. A., Astl, M., Tschiderer, L., Pfeifer, B. E., Gaber, M., Schennach, H., & Willeit, P. (2022) · Viruses · doi:10.3390/v14030568 · Cited by 25
“The antibody level differed significantly between partially vaccinated participants (median 70 BAU/mL [IQR 15-259]), fully vaccinated participants (757 [2651,829]), unvaccinated participants with prior SARS-CoV-2 infection (38 [17-87]), and unvaccinated participants without prior SARS-CoV-2 infection (0.”
BackgroundManipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
Saha, T., Sinha, S., Harfoot, R., Quiñones‐Mateu, M. E., & Das, S. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071432 · Cited by 27
Jiang, F., Zhao, Y. C., Bai, J., Yang, X., Zhang, J., Lin, D., & Li, X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273285 · Cited by 26
“Remarkable achievement of COVID-19 vaccine development was observed in large, randomized-controlled trials [10, 11], where several vaccines were found to be safe and efficacious in preventing symptomatic COVID-19, such as mRNA vaccines (e.”
BackgroundImmunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
Akache, B., Renner, T. M., Stuible, M., Rohani, N., Donates, Y. C., Deschatelets, L., Dudani, R., Harrison, B. A., Gervais, C., Hill, J. J., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00540-7 · Cited by 24
Gemmati, D., Longo, G., Gallo, I., Silva, J. A., Secchiero, P., Zauli, G., Hanau, S., Passaro, A., Pellegatti, P., Pizzicotti, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1028081 · Cited by 24
Al-Sheboul, S. A., Brown, B., Shboul, Y., Fricke, I., Imarogbe, C., & Alzoubi, K. H. (2022) · Vaccines · doi:10.3390/vaccines11010051 · Cited by 25
“3% efficiency in preventing SARS-CoV-2 infections in phase 3 clinical trials [66].”
BackgroundMultifunctional rolling circle transcription-based nanomaterials for advanced drug delivery
Ma, X., Zhang, Y., Huang, K., Zhu, L., & Xu, W. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122241 · Cited by 24
Finnegan, D., Tocmo, R., & Loscher, C. E. (2023) · Nutrients · doi:10.3390/nu15153371 · Cited by 26
“With an estimated six-month immunity provided by the vaccines as antiviral therapy for the prevention of COVID-19 infection, alternative methods to augment protection against viral invasion are highly desirable [16,17].”
BackgroundLi, G., Gerlovin, H., Muñiz, M. J. F., Wise, J. K., Madenci, A. L., Robins, J. M., Aslan, M., Cho, K., Gaziano, J. M., Lipsitch, M., et al. (2023) · Epidemiology · doi:10.1097/ede.0000000000001709 · Cited by 25
Huang, L., Zhao, F., He, M., Fang, Y., Ma, X., Lu, S., Li, E., Xiao, H. Q., Zhu, H., Wang, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.002 · Cited by 24
Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms
Pineda-Peña, A.-C., Hasegawa, K., Pavot, V., Berry, C., Combadière, B., Cortés-Garcia, G., McDermott, A. B., & Sridhar, S. (2025) · npj Vaccines · doi:10.1038/s41541-025-01302-x · Cited by 25
“Initial trialsevaluating themRNAand adjuvanted proteinvaccines have demonstrated 95 – 100% vaccine ef fi cacy 139 .”
Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
Anthony, D. P. S., Sivakumar, K., Venugopal, P., Sriram, D. K., & George, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01022-9 · Cited by 23
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
Gandolfo, C., Anichini, G., Mugnaini, M., Bocchia, M., Terrosi, C., Sicuranza, A., Savellini, G. G., Gozzetti, A., Franchi, F., & Cusi, M. G. (2022) · Vaccines · doi:10.3390/vaccines10020171 · Cited by 24
“BNT162b2 is a lipid nanoparticle formulated nucleoside-modified messenger RNA (mRNA), encoding SARS-CoV-2 spike (S) protein, stabilized in the prefusion conformation [4].”
BackgroundThe Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 27
“The BioNTech/Pfizer vaccine exhibited a 95% efficacy in phase 3 of clinical trials [26], and more recently, another study was released showing that efficacy was maintained over a period of 6 months, irrespective of previous SARS-CoV-2 infections [27].”
MethodDoherty, J., Morain, N. O., Stack, R., Girod, P., Tosetto, M., Inzitiari, R., Sheridan, J., Cullen, G. J., McDermott, E., Buckley, M., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac029 · Cited by 25
Li, Y. E., Wang, S., Reiter, R. J., & Ren, J. T. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.026 · Cited by 25
Pallathadka, A., Chang, H., & Han, D. (2022) · Environmental Research Health · doi:10.1088/2752-5309/ac8ac2 · Cited by 24
Khawaja, F., Papanicolaou, G. A., Dadwal, S., Pergam, S. A., Wingard, J. R., Boghdadly, Z. E., Abidi, M. Z., Waghmare, A., Shahid, Z., Michaels, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.10.010 · Cited by 24
Alam, M. S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13285 · Cited by 25
Bates, J. T., Farmer, A. P., Bierdeman, M. A., Ederer, D. R., Carney, L. S., Montgomery, D. D., Lirette, S. T., & Marshall, G. D. (2022) · Vaccines · doi:10.3390/vaccines10040512 · Cited by 23
“The recently approved mRNA vaccines are highly effective at reducing infection and morbidity in the general population [11,12] and have been recommended for individuals with obesity [13].”
BackgroundPanda, S., Eaton, E. J., Muralikrishnan, P., Stelljes, E. M., Seelig, D. M., Leyden, M. C., Gilkey, A. K., Barnes, J. T., Morrissey, D. V., Sarupria, S., et al. (2025) · JACS Au · doi:10.1021/jacsau.5c00084 · Cited by 24
Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress
Li, S., Zheng, L., Zhong, J., & Gao, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253009 · Cited by 24
“Moreover, a six-month follow-up study of individuals aged 12 and older who received two doses of BNT162b2 reported an efficacy rate exceeding 86% and a favorable long-term safety profile [92].”
COVID-19 boosters in rich nations will delay vaccines for all
Chagla, Z., & Pai, M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01494-4 · Cited by 22
Richterman, A., Behrman, A., Brennan, P. J., O’Donnell, J. A., Snider, C. K., & Chaiyachati, K. H. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac454 · Cited by 24
Addressing COVID-19 vaccine hesitancy
Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 24
Self-citationmRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 23
Coronavirus Disease 2019 (COVID-19) Vaccination in Pregnancy
Prabhu, M., & Riley, L. E. (2023) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005100 · Cited by 22
Nguyễn, V. H., Boileau, C., Bogdanov, A., Sredl, M., Bonafede, M., Ducruet, T., Chavers, S., Rosen, A., Martin, D., Buck, P. O., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad288 · Cited by 23
“Data from clinical trials indicated high vaccine efficacy through to 6 months post-vaccination, particularly for mRNA vaccines [1-7].”
MethodEffectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Cheung, Y. Y. H., Lau, E. H. Y., Yin, G., Lin, Y., Cowling, B. J., & Lam, K. F. (2023) · Emerging infectious diseases · doi:10.3201/eid3001.230414 · Cited by 24
“Similar to the case for CoronaVac, abundant clinical trials and studies have proven safety and efficacy of the Comir - naty vaccine against COVID-19–related hospitalization, death, and severe outcomes ( 16 – 19 ).”
Result
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.